Amyloid-β Inhibitor

Benzenesulphonamide (Standard) is the analytical standard of Benzenesulphonamide (HY-101087). This product is intended for research and analytical applications. Benzenesulphonamide (Compound 1) is a carbonic anhydrase inhibitor. Benzenesulphonamide exhibits CA II inhibitory activity. Benzenesulphonamide reduces ROS and improves the gene expression of amyloid-β40 and 42. Benzenesulphonamide is beneficial for Alzheimer's disease. Benzenesulphonamide derivatives have anticancer, anti-inflammatory, and anticonvulsant activities. Benzenesulphonamide can be used in the research of Alzheimer's disease, epilepsy, inflammatory diseases, leukemia, melanoma, lung cancer, and colon cancer.

PMN310 is a monoclonal antibody targeting amyloid-β oligomers (AβO). PMN310 prevents AβO-induced memory loss and reduces synaptic loss and inflammation in vivo. PMN310 is potentially useful in Alzheimer's disease research.

AChE/BChE-IN-32 (Compound 4a) is an AChE and BChE inhibitor, with K_i values of 2.48 and 0.696 μM respectively. AChE/BChE-IN-32 inhibits Aβ aggregation and exhibits a strong ABTS•+ scavenging ability (TEAC = 2.40). AChE/BChE-IN-32 shows significant neuroprotective activity in glutamate and hydrogen peroxide-induced oxidative stress models. AChE/BChE-IN-32 can be used for the study of Alzheimer's disease.

Anti-Amyloid Beta Antibody (scFv59) is a human antibody expressed in CHO cells, targeting Amyloid-β. Anti-Amyloid Beta Antibody (scFv59) can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).

Spinosin (Standard) is the analytical standard of Spinosin. This product is intended for research and analytical applications. Spinosyn is a kind of effective C-saccharide, which has a protective effect. Spinosyn is active through Nrf2/HO-1 pathway inhibition Aβ1-42's production and combination.

γ-Secretase modulator 12 (Compound 1a) is a γ-secretase modulator that can selectively decrease amyloid-β42 (Aβ42) levels (IC₅₀ of 0.39 µM). γ-Secretase modulator 12 can be used for Alzheimer’s disease research. γ-Secretase modulator 12 has a good brain/plasma ratio (Kp, brain = 0.72) in mice.

LY-2434074 is a selective β-secretase (BACE) inhibitor with an IC₅₀ <100 nM. LY-2434074 can inhibit amyloid-β (Aβ₄₀ and Aβ₄₂) production. LY-2434074 can be used for the research of neurological disease, such as Alzheimer's disease.

TPI-1917-49 is an agent that can cross the blood-brain barrier and reduce amyloid β (Aβ). TPI-1917-49 reduces the production of Aβ peptide segments by promoting the non-amyloidogenic pathway of amyloid precursor protein (APP) (increasing the generation of sAPPα mediated by α-secretase). TPI-1917-49 reduces amyloid plaques in mouse models. TPI-1917-49 can be used in Alzheimer's disease research.

Amyloid-β-Drp1 PPI-IN-1 is an Amyloid-β-Drp1 protein-protein interaction inhibitor. Amyloid-β-Drp1 PPI-IN-1 inhibits Aβ-Drp1 interaction and decreases Drp1 and Aβ levels. Amyloid-β-Drp1 PPI-IN-1 inhibits excessive mitochondrial fission and promotes mitochondrial fusion and biogenesis. Amyloid-β-Drp1 PPI-IN-1 also alleviates oxidative stress and improves mitochondrial function, and can be used for Alzheimer's disease research.

Methyl tridecanoate-d₂₅ is the deuterium labeled Methyl tridecanoate. Methyl tridecanoate moderately inhibits β-amyloid aggregation. Methyl tridecanoate weakly inhibits acetylcholinesterase (AChE).

MEDI-1814 is a fully human IgG1 antibody that targets the C terminus of Aβ42. MEDI-1814 binds to and sweeps away the circulated Aβ peptides, hence, restricting them from aggregating into toxic oligomers. MEDI-1814 can be used for the study of Alzheimer's diseases. The isotype control for MEDI-1814 can refer to Human IgG1 kappa, Isotype Control (HY-P99001).

CLR01 sodium is a blood-brain barrier-permeable anti-aggregation agent. CLR01 sodium inhibits the de novo aggregation of Amyloid-β 40/42, α-synuclein, IAPP, tau protein and SOD1. CLR01 sodium reduces amyloid plaque burden in the cortex of triple-transgenic mice and improves the memory and motor abilities of these mice. CLR01 sodium can be used in research related to Alzheimer's disease, Parkinson's disease, and amyotrophic lateral sclerosis (ALS).

Santacruzamate A (Standard) is the analytical standard of Santacruzamate A. This product is intended for research and analytical applications. Santacruzamate A (CAY-10683, STA) is a potent and selective HDAC2 inhibitor with an IC50 of 119 pM. STA also exerts neuroprotective property against amyloid-β protein fragment 25–35. STA can be used for cancer and neurological disease research[1][2].

SAR228810 is a humanized IgG4 monoclonal antibody inhibitor targeting amyloid β (Aβ) with a KD? of ?0.43 ?nM for protofibrillar Aβ over monomeric Aβ. SAR228810 significantly inhibits the brain amyloid plaque formation and oligomer-induced synaptic dysfunction and neurite loss. SAR228810 has significant protection against Aβ-mediated neuritotoxicity. MINT1526A can be used for Alzheimer’s disease imaging and immunotherapy research.

Aβ-IN-1 is a Aβ1-42 aggregation inhibitor. Aβ-IN-1 inhibits Aβ1-42 self-aggregation in vitro by delaying the exponential growth phase or reduces the quantity of fibrils in the steady state. Aβ-IN-1 can be used for the research of conformational disorders.

Cbz-Gly-Pro-Ala-O-cinnamyl (compound 25) is a small peptide targeting BACE-1 and AChE with the IC₅₀ values of 0.02 μM and 1 μM, respectively. Cbz-Gly-Pro-Ala-O-cinnamyl shows neuroprotective effect and can be used for study of Alzheimer’s disease.

Aβ1–42 aggregation inhibitor 3 (Compound 3b) is an acetylcholinesterase (AChE) and butyrylcholinesterase (BuChE) inhibitor (IC₅₀ values are 1.634 and 0.0285 μM, respectively). Aβ1–42 aggregation inhibitor 3 can inhibit the aggregation of Aβ_1-42. Aβ1–42 aggregation inhibitor can be used in Alzheimer's disease (AD) research.

hBChE-IN-1 (compound 4), a quinolizidinyl derivative, is a potent hBChE inhibitor (IC₅₀=7 nM) and highly selective over hAChE. hBChE-IN-1 shows inhibitory activity against tau and Aβ₄₀ protein aggregation, with IC₅₀ values of 20 and 4.3 μM, respectively. hBChE-IN-1 can be used for Alzheimer's disease research.

AChE/Aβ-IN-4 is a dual inhibitor of acetylcholinesterase (AChE) and β-amyloid (Aβ) aggregation, with the IC₅₀ values of 1.72 ± 0.18 μM and 1.42 ± 0.3 μM, respectively. AChE/Aβ-IN-4 plays an impotant role in neurological disorders, such as Alzheimer’s disease.

P021 (Peptide 021) is an orally active, blood-brain barrier penetrant neurotrophic/neurogenic pentapeptide derived from the most active region of ciliary neurotrophic factor (CNTF). P021 competitively inhibits leukemia inhibitory factor (LIF) and promotes BDNF transcription. P021 targets neurogenesis and synaptic plasticity. P021 prevents neurodegeneration, Amyloid-β pathology, tau protein pathology and cognitive deficits, rescues episodic memory impairment and reduces mortality in 3xTg-AD mice. P021 is applicable to the research of Alzheimer's disease.